NasdaqCM:NYMX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. More Details


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Nymox Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NYMX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-18.1%

NYMX

-2.4%

US Biotechs

-4.6%

US Market


1 Year Return

-2.5%

NYMX

26.7%

US Biotechs

11.5%

US Market

Return vs Industry: NYMX underperformed the US Biotechs industry which returned 26.7% over the past year.

Return vs Market: NYMX underperformed the US Market which returned 11.5% over the past year.


Shareholder returns

NYMXIndustryMarket
7 Day-18.1%-2.4%-4.6%
30 Day-22.3%-1.7%-0.9%
90 Day-38.7%-3.0%2.2%
1 Year-2.5%-2.5%28.9%26.7%14.0%11.5%
3 Year-43.1%-43.1%18.2%12.3%34.5%25.6%
5 Year-46.4%-46.4%7.1%-0.6%73.0%53.6%

Price Volatility Vs. Market

How volatile is Nymox Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nymox Pharmaceutical undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Nymox Pharmaceutical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Nymox Pharmaceutical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Nymox Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

25.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nymox Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Nymox Pharmaceutical performed over the past 5 years?

5.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NYMX is currently unprofitable.

Growing Profit Margin: NYMX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NYMX is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.

Accelerating Growth: Unable to compare NYMX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NYMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: NYMX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Nymox Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: NYMX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NYMX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NYMX is debt free.

Reducing Debt: NYMX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NYMX has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: NYMX is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Nymox Pharmaceutical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NYMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NYMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NYMX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NYMX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NYMX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.3yrs

Average board tenure


CEO

Paul Averback (69 yo)

no data

Tenure

US$2,317,995

Compensation

Dr. Paul Averback, M.D., D A.B.P., has been the President of Nymox Pharmaceutical Corporation since September 1995 and serves as its Chief Executive Officer. Dr. Averback is the Founder of Nymox Pharmaceut ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD2.32M) is above average for companies of similar size in the US market ($USD593.13K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Paul Averback
Founderno dataUS$2.32m35.53%
$ 52.9m
Randall Lanham
General Counsel14.33yrsUS$478.96k0.20%
$ 298.1k
M. Richard Cutler
Lead Independent Directorno datano datano data
David Morse
Independent Director14.33yrsno data0.00052%
$ 773.9
James Robinson
Independent Director5.25yrsno data6.21%
$ 9.2m

14.3yrs

Average Tenure

63yo

Average Age

Experienced Board: NYMX's board of directors are seasoned and experienced ( 14.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.


Top Shareholders

Company Information

Nymox Pharmaceutical Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nymox Pharmaceutical Corporation
  • Ticker: NYMX
  • Exchange: NasdaqCM
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$148.821m
  • Shares outstanding: 76.32m
  • Website: https://www.nymox.com

Location

  • Nymox Pharmaceutical Corporation
  • Bay & Deveaux Streets
  • 2nd Floor
  • Nassau
  • Bahamas

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NYMXNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDNov 1997
NYMDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 1997

Biography

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 23:44
End of Day Share Price2020/10/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.